September 18, 2026 — Scheduled research review

Home · Latest · Calendar

Worldwide human research with U.S. availability called out separately. All 28 active topics received focused discovery and source checks. Searches covered the seven-day overlap from retained successful-check dates, generally September 5–18 (September 6 for the newer September 13 baselines), plus named historical gaps. None of the 28 topics received an exhaustive complete-topic re-review: successful-check timestamps are unchanged. Unresolved gaps remain queued for the next run.

Findings and evidence corrections

Neuro-DORA studies sleep treatment and neurodegeneration biomarkers

Source date: 2026-09-18. Evidence: recovered baseline; current registry update.

New to this notebook, Neuro-DORA is an existing small trial of lemborexant and blood biomarkers, not a newly launched dementia-prevention trial. NCT06823752, Woolcock Institute Australia; 20 planned adults with insomnia, randomized masked crossover, two weeks lemborexant versus placebo separated by washout. Primary pTau181 ratio; pTau217, amyloid, NfL and GFAP secondary. Actual start May 13, 2025; September 18 record recruiting, no results.

Limitations: Brief biomarker experiment, not dementia incidence, cognitive function or durable insomnia benefit; update alone does not establish a substantive protocol change.

Safety: No results posted; do not infer neuroprotection from study rationale.

U.S. status: Lemborexant/Dayvigo is an insomnia medicine; this study does not add an Alzheimer-prevention indication.

Next milestone: Registry estimate: Completion December 2027; no promised publication date.

Neuro-DORA registry.

Primary topic: Sleep therapies and sleep disorders. Stable event key: neuro_dora_registry_baseline_recovered_2026_09_18.

Patidegib Gorlin-syndrome study completes follow-up; results forecast for November

Source date: 2026-09-17. Evidence: Sponsor development milestone.

The phase 3 SGT-610 study has completed its final patient visit; the sponsor forecasts topline results in late November 2026. SGT-610-01 tests topical patidegib 2% versus vehicle for 12 months to prevent new facial basal-cell carcinomas in adults with Gorlin syndrome. It enrolled 113 people; 102 completed. Database lock and analysis are next, with assignments still blinded.

Limitations: No efficacy or comparative safety result is released. This inherited high-risk cancer-prevention setting does not establish cosmetic benefit or prevention in the general population.

Safety: The completed-visit announcement contains no new outcome-level safety analysis.

U.S. status: Investigational; trial completion and designations are not approval.

Next milestone: Late November 2026 topline: sponsor forecast, not a scheduled day.

Sol-Gel, September 17.

Primary topic: Cancer treatment, vaccines and recurrence prevention. Stable event key: sgt610_2026-09-17_last_visit.

Ketamir-2 prepares a controlled neuropathy trial

Source date: 2026-09-17. Evidence: Sponsor protocol-development announcement.

MIRA submitted a phase 2a chemotherapy-induced neuropathy protocol for ethics review; site initiation is targeted for Q1 2027, not confirmed underway. After FDA feedback, the planned randomized double-blind crossover study compares oral Ketamir-2 300 mg, 600 mg and placebo across three seven-day periods with washouts in adults with persistent moderate-to-severe chemotherapy-induced peripheral neuropathy. Enrollment size and a matched registry identifier were not established in the release.

Limitations: Healthy-volunteer phase 1 tolerability does not establish pain relief, function or chronic safety in patients. This oral NMDA-modulator program is distinct from approved suzetrigine and from psychedelic depression trials.

Safety: Sponsor reports no serious events or dose-limiting toxicity in phase 1; phase 2 comparative safety and CNS effects remain unmeasured.

U.S. status: Investigational; FDA protocol review and an active IND are not marketing approval.

Next milestone: Q1 2027 site initiation is conditional on IRB review and activation. An October 5–6 presentation concerns phase 1/development, not phase 2 efficacy.

MIRA, September 17.

Primary topic: Non-opioid pain treatments. Stable event key: ketamir2_2026-09-17_phase2_protocol.

Finerenone gains U.S. approval for CKD associated with type 1 diabetes

Source date: 2026-09-17. Evidence: Regulatory action; September 2026 U.S. prescribing information verified.

The formerly pending type 1 diabetes indication is now approved. The label specifically describes UACR reduction expected to reduce sustained eGFR decline and end-stage kidney disease. FINE-ONE randomized 242 adults and measured albuminuria over six months. The new label infers kidney-event benefit from type 2 diabetes outcome trials together with pharmacodynamic and safety evidence in type 1 diabetes. The approval expands the indication; it does not represent a new trial directly demonstrating dialysis prevention.

Limitations: Bayer announced the approval on September 17; the dated FDA action letter was not retrieved. The indication should not be generalized to all non-diabetic CKD.

Safety: Hyperkalemia remains the principal monitoring issue; strong CYP3A4 inhibitors and adrenal insufficiency are contraindications. Pooled 14% versus 6.9% hyperkalemia figures in the label belong to type 2 diabetes trials, not FINE-ONE.

U.S. status: Approved in the U.S. for adults with CKD associated with type 1 diabetes.

Next milestone: Implementation and longer-term evidence; no firm date for the next readout was verified.

Bayer U.S. announcement; U.S. prescribing information, revised September 2026.

Primary topic: Kidney preservation and earlier detection. Stable event key: finerenone_2026-09-17_US-T1D-CKD-approval.

Deramiocel two-year follow-up scheduled at World Muscle Society

Source date: 2026-09-17. Evidence: Sponsor conference/development announcement.

Capricor will present HOPE-3 extension and delayed-start analyses in Duchenne muscular dystrophy. Of 106 participants originally randomized, 82 reached the 24-month timepoint: 40 originally assigned to deramiocel and 42 originally assigned to placebo. WMS runs September 29–October 3, with the oral presentation scheduled for October 3. The second year is open-label, with delayed-start and natural-history analyses.

Limitations: The notice provides no numerical 24-month effect or safety estimates. The extension does not maintain a randomized placebo comparison or establish general muscle-preservation efficacy. Earlier 12-month results are baseline evidence, not new September 17 efficacy findings.

Safety: New long-term safety tables pending.

U.S. status: Investigational. The sponsor lists an FDA target action date of November 22, 2026; this does not guarantee approval.

Next milestone: WMS, September 29–October 3, with the oral presentation on October 3. FDA target action date: November 22, 2026.

Capricor original September17 release.

Primary topic: Muscle building and preservation. Stable event key: deramiocel_2026-09-17_WMS-schedule.

Safety detail added to already recorded AgelessRx pilot

Source date: September 2 pilot; safety detail checked September 18. Evidence: Evidence correction to existing pilot.

The current sponsor page reports a serious adverse event omitted from the notebook summary. It does not establish that a new safety event occurred on September 17. The same 90-day pilot enrolled 26 participants and analyzed 18. Seven of 26 participants experienced adverse events, and three withdrew. One myocardial infarction occurred in the multi-therapy arm and was assessed as possibly associated with physical activity. The page now says it was last updated on September 17; earlier findings were first recorded as September 2.

Limitations: Bundled intervention, small groups, sponsor-only reporting and attrition; no causal attribution to any drug established. Do not equate unchanged laboratory panels with an absence of adverse events.

Safety: The myocardial infarction was a serious adverse event. Mixed cognitive and maximal oxygen-uptake results should also remain visible.

U.S. status: No approval of a longevity drug or regimen is established.

Next milestone: The sponsor plans a one-year trial with 186 participants; registration and actual start were not confirmed.

AgelessRx current pilot report.

Primary topic: Longevity and healthspan trials. Stable event key: AgelessRx_2026-09-17_pilot-safety-detail.

Resistance-training study during tirzepatide treatment is listed as recruiting

Source date: 2026-09-17. Evidence: Trial registry; prospective study to follow.

A randomized study will measure whether resistance training preserves contractile thigh muscle during tirzepatide treatment. The Technical University of Munich study, NCT07777575, plans to enroll 150 adults with obesity and compare 24 weeks of resistance training with usual care. MRI endpoint assessment is blinded. The primary endpoint is change in contractile thigh muscle volume. The record was first posted on August 20 and updated on September 17; the trial is listed as recruiting.

Limitations: September 7 start is still estimated in the primary registry despite mirrors calling it actual. Muscle volume is distinct from strength and everyday function; no results available. This is a training adjunct study, not a new muscle drug.

Safety: Prospective safety data pending.

U.S. status: Approved tirzepatide is the background treatment; no new indication from registration.

Next milestone: Estimated primary/overall completion May 31, 2027, not a promised readout date.

NCT07777575 current primary registry.

Primary topic: Muscle building and preservation. Stable event key: tirzepatide-resistance-training_2026-09-17_registry.

New study targets emotional blunting during antidepressant treatment

Source date: 2026-09-17. Evidence: new trial registration.

A newly registered phase 4 study will examine adjunctive lumateperone for emotional blunting in MDD. NCT07824206; Future Options Research with J&J collaboration, planned 30 adults, open-label single group. Eight-week Oxford Depression Questionnaire change is the primary endpoint. Registry status not yet recruiting; September 2026 start remains estimated.

Limitations: No results or comparator. Emotional blunting can reflect illness and treatment; the design cannot isolate a drug-causal explanation or comparative benefit.

Safety: No study safety results yet. Phase 4 designation does not establish benefit for this specific symptom.

U.S. status: Lumateperone has an adjunctive MDD indication, but this specific emotional-blunting claim is being studied.

Next milestone: Registry estimate: Primary completion January 2028; overall completion March 2028. Not promised publication dates.

New September 17 registry.

Primary topic: Mental-health treatments, SSRIs and newer antidepressants. Stable event key: lumateperone_emotional_blunting_registration_2026_09_17.

KetSet will compare the therapeutic framing of ketamine

Source date: 2026-09-17. Evidence: new randomized study registration.

KetSet will compare psychedelic versus biomedical framing while keeping ketamine treatment the same. NCT07824973, Sweden; planned 120 adults with TRD, randomized parallel arms, participants/staff unblinded and outcome assessors masked. Primary endpoint MADRS change at week 12. Both groups receive six infusions; support/context differs. Not yet recruiting, September start estimated.

Limitations: No results. It tests context, not ketamine versus placebo or psilocybin. Registry title says open-label while design clarifies assessor masking.

Safety: Adverse events, discontinuation, suicidality and longer-term hospital outcomes are planned, not demonstrated.

U.S. status: No U.S. approval change; intravenous ketamine depression use remains distinct from intranasal esketamine approval.

Next milestone: Registry estimate: Primary completion December 2029; overall completion August 2030.

KetSet registry, first posted September 17.

Primary topic: Mental-health treatments, SSRIs and newer antidepressants. Stable event key: ketset_framing_registration_2026_09_17.

Small sponsor studies explore skin care after medication-associated weight loss

Source date: 2026-09-17. Evidence: sponsor conference report; preliminary human studies.

Allergan reports early skin-quality improvements in people taking weight-loss medicines, from two very small single-center studies. One 12-week skincare study had nine completers; a six-week DiamondGlow plus skincare study had 11 people with at least one post-treatment assessment. Selected investigator-rated dryness, texture, crepiness and other measures improved.

Limitations: The release supplies no randomized comparator, numerical effect sizes, uncertainty intervals or enrollment denominators. Its perceived younger-appearance claims are participant impressions, not biological-age reversal or evidence of substantial loose-skin correction.

Safety: Adverse-event counts were not supplied; do not describe the regimens as proven safe.

U.S. status: No new FDA indication or approval announced.

Next milestone: Posters at Science of Skin Summit September 17–20; full controlled replication and durability results undated.

AbbVie original release.

Primary topic: Skin aging, laxity and regeneration. Stable event key: Allergan_2026-09-17_post_weightloss_skinquality_pilots.

Mosunetuzumab combination meets phase 3 lymphoma endpoint

Source date: 2026-09-16. Evidence: Sponsor topline; randomized phase 3.

CELESTIMO reports improved progression-free survival with mosunetuzumab plus lenalidomide in previously treated follicular lymphoma; overall survival is immature. NCT04712097 compares mosunetuzumab plus lenalidomide with rituximab plus lenalidomide after at least one prior treatment. The registry lists 478 actual participants. Genentech reports that the interim primary endpoint was met, without releasing a hazard ratio or absolute PFS estimates.

Limitations: PFS benefit must not be called a demonstrated survival benefit. The study supports a potential earlier-line indication and confirmatory regulatory review; neither action is completed by the topline announcement.

Safety: Sponsor reports no new safety signal, but comparative adverse-event tables are pending. Known mosunetuzumab risks include serious cytokine-release syndrome and infections.

U.S. status: Existing third-line-or-later monotherapy approval is separate from the investigational second-line combination.

Next milestone: Full results at an unnamed upcoming medical meeting and regulatory submissions; no firm date.

Genentech, September 16; CELESTIMO registry.

Primary topic: Cancer treatment, vaccines and recurrence prevention. Stable event key: celestimo_2026-09-16_pfs_topline.

Small psilocybin subgroup study includes personality disorders

Source date: 2026-09-16. Evidence: peer-reviewed accepted article; exploratory secondary analysis.

A September 16 paper reports a ten-person TRD subgroup with co-occurring personality disorders, usually excluded from psychedelic trials. NCT05029466; nine had cluster B and one cluster C personality disorder. Three dropped out. Mean MADRS was 30.4 before treatment and 22.3 at six months; trajectories varied substantially. Registry parent trial enrolled 30 and completed in 2023.

Limitations: No controlled efficacy estimate for this subgroup; tiny selected sample, secondary analysis and attrition. Abstract reviewed; accepted-manuscript PDF access failed. Do not describe this as proven personality-disorder treatment or suicide prevention.

Safety: No serious adverse events reported in abstract; inadequate size to establish psychiatric safety or exclude uncommon harm.

U.S. status: Psilocybin remains investigational for these indications.

Next milestone: No announced date: Larger controlled studies and complete safety reporting needed.

Lipsitz et al., npj Mental Health Research, September 16; Parent registry.

Primary topic: Psilocybin and related therapies. Stable event key: psilocybin_trd_personality_subgroup_2026_09_16.

PST-611 geographic-atrophy presentation scheduled for October 2

Source date: 2026-09-16. Evidence: announced conference presentation; recovered phase 1 baseline.

PulseSight announced an October 2 EURETINA presentation. The six-person phase 1 findings substantially repeat its May ARVO report, rather than constituting a fresh efficacy trial. PST-611-CT1 / NCT07024732 studies nonviral transferrin-gene delivery. Sponsor treated analysis: six patients, two dose levels, 16 weeks. May report says BCVA remained stable and cites exploratory anatomical/patient-reported signals. Registry lists eight enrolled and completion April 7; enrollment is not necessarily the treated analysis denominator.

Limitations: Uncontrolled, safety-focused study with no quantified comparative efficacy. September release also says twelve-month study in its boilerplate despite four-month follow-up in the body; do not infer validated twelve-month benefit.

Safety: May report: predominantly mild ocular AEs, two moderate events, no treatment-emergent SAE or intraocular inflammation reported.

U.S. status: Investigational, not U.S.-approved.

Next milestone: Scheduled conference presentation: EURETINA Session 6 #138, 13:05 in Vienna. May sponsor forecast: phase 2a start H2 2026 and results 2028, contingent on authorization; actual start not verified.

September 16 announcement; May 11 original topline; PST-611-CT1 registry.

Primary topic: Hearing and vision preservation/restoration. Stable event key: pst611_euretina_presentation_announced_2026_09_16.

Dual-target RNAi lowers LDL, ApoB and triglyceride biomarkers

Source date: 2026-09-15. Evidence: Sponsor interim topline.

Arrowhead reports early ARO-DIMER-PA human data targeting PCSK9 and APOC3 with one RNAi molecule. The placebo-controlled phase 1/2a dose-escalation study, NCT07223658, plans to enroll up to 78 adults with mixed hyperlipidemia. Reported mean maximal reductions after a single dose were 54% for LDL-C, 50% for ApoB, 73% for triglycerides and 61% for non-HDL cholesterol. Target-protein reductions were 72% for PCSK9 and 88% for APOC3.

Limitations: Analyzed cohort sizes, uncertainty intervals, placebo-adjusted estimates and common measurement timepoints were not provided. Maximal biomarker reductions do not establish cardiovascular benefit and cannot support a comparable endpoint plot without further details.

Safety: Injection-site events and headache were the most common adverse events. No drug-related serious adverse events were reported. Safety with multiple doses remains under study.

U.S. status: Investigational; no U.S. approval.

Next milestone: Additional congress details are undated. The registry lists the trial as recruiting, with estimated primary completion on September 30, 2026 and overall completion in July 2027. These are not promised results dates.

Arrowhead September 15 release; ARO-DIMERPA registry.

Primary topic: Broad cardiovascular prevention, lipids and screening. Stable event key: aro-dimer-pa_2026-09-15_phase1-2a-interim.

Eloralintide plus tirzepatide phase 2 presentation scheduled

Source date: 2026-09-15. Evidence: Official sponsor conference schedule.

Lilly specifies the upcoming eloraTZP phase 2 disclosure at EASD. Eloralintide plus tirzepatide results in adults with overweight or obesity and type 2 diabetes are scheduled for September 30, 16:30–17:30 CEST. Retatrutide/TRIUMPH-2 is scheduled for September 30, 08:30–09:30 CEST; Foundayo/ACHIEVE is scheduled for October 1, 08:30–09:15 CEST.

Limitations: The announcement contains no new numerical eloraTZP efficacy or safety results. ACHIEVE-4 estimates repeat April 16 data and should not be presented as new September findings or proof of superiority: four-component MACE HR 0.84 (95% CI 0.59–1.20); three-component MACE HR 0.77 (95% CI 0.52–1.13).

Safety: The new combination safety presentation is pending.

U.S. status: The combination is investigational; approved indications for its components do not establish approval of the combination.

Next milestone: The eloraTZP symposium is scheduled for September 30, 2026.

Lilly EASD announcement.

Primary topic: GLP-1 and related metabolic therapies. Stable event key: lilly_2026-09-15_EASD-eloratzp-schedule.

PP405 AWAKEN enters the registry as a planned Phase 2/3 study

Source date: 2026-09-15. Evidence: trial-registry update.

AWAKEN is now registered, but the latest record still says not yet recruiting. This makes Pelage’s late-stage plan more concrete without confirming first dosing. NCT07819435; Pelage; 600 planned men aged 18–55, Norwood-Hamilton IV/V. Randomized 1:1 PP405 0.05% topical gel versus vehicle for 24 weeks; active continues through week 52 while vehicle participants rerandomize. Primary endpoint: week 24 change in non-vellus target-area hair count; secondary participant-rated scalp coverage. First posted September 15, last updated September 18.

Limitations: No results. Men only and selected severity; registration does not establish efficacy or launch. Mirror dates September 30/December 31 are false precision: original gives month only.

Safety: Longer safety follow-up is planned, not observed evidence.

U.S. status: Investigational; no U.S. marketing approval.

Next milestone: September 2026 estimated start; December 2027 estimated primary completion; June 2028 estimated final completion. Public readout date unannounced.

ClinicalTrials.gov AWAKEN; Original API.

Primary topic: Hair loss, restoration and graying. Stable event key: PP405_2026-09-15_AWAKEN_phase2_3_registration.

SPLENDID improves cross-ancestry polygenic prediction in biobank analyses

Source date: 2026-09-14. Evidence: Peer-reviewed human-genetic methods study.

SPLENDID models ancestry as a continuum and improves prediction in diverse biobank populations; clinical benefit from using it has not been tested. The study combined simulations with All of Us (224,364 people) and UK Biobank (340,140). It reports improved prediction, particularly for non-European and admixed ancestries, without requiring discrete ancestry labels.

Limitations: This is prediction/model validation, not a randomized test of risk-guided prevention, and not validation of embryo ranking or long-term offspring benefit. The original abstract was retrieved through Europe PMC; full model-performance tables were not appraised.

Safety: Clinical harms and downstream management effects were not evaluated.

U.S. status: Publication does not establish a newly approved U.S. screening test.

Next milestone: Prospective calibration, implementation and outcome studies; no firm date.

Nature Methods, September 14; Primary abstract.

Primary topic: Genetic screening and risk prediction. Stable event key: splendid_2026-09-14_prediction_validation.

Non-incretin CRB-913 reports phase 1b weight-loss data

Source date: 2026-09-14. Evidence: Sponsor topline.

The oral peripheral CB1 inverse agonist adds a non-incretin obesity program to the broader metabolic watch. CANYON-1, NCT07310901, randomized 254 U.S. adults with obesity without diabetes. After 12 weeks of treatment, efficacy-estimand weight loss was 2.8%, 3.3% and 5.0% across active doses versus 0.0% with placebo (all p < .0001). The highest-dose arm included 62 participants; placebo included 66. Four weeks of follow-up followed treatment. The registry retains an older May 29 snapshot, with estimated enrollment of 252 and no posted results; preserve the later sponsor-reported analysis population.

Limitations: Short phase 1b study, no uncertainty intervals or long-term outcomes; sponsor GLP-1 comparisons are cross-trial, not head-to-head. Do not label CRB-913 an incretin or add it to hormone-mimetic plots without explicit scope change.

Safety: Adverse-event discontinuations ranged from 3.1% to 13.1%; irritability affected 6.2%–9.7% across active doses versus 0% with placebo. No serious/severe psychiatric event or suicidality reported. Gastrointestinal symptoms occurred; long-term neuropsychiatric safety remains unestablished.

U.S. status: Investigational.

Next milestone: A detailed presentation is scheduled for ObesityWeek, November 14–17, 2026. The sponsor targets a phase 2 start in the first half of 2027.

Corbus September14 release; CANYON-1 registry.

Primary topic: GLP-1 and related metabolic therapies. Stable event key: CRB-913_2026-09-14_CANYON1-topline.

IVIG add-on improves early inflammatory-myopathy disease activity

Source date: 2026-09-14. Evidence: Peer-reviewed randomized human trial.

TIME IS MUSCLE supports earlier IVIG add-on in a small newly diagnosed inflammatory-myopathy population. The double-blind trial randomized 44 adults, all treated with high-dose prednisone. The reported primary-outcome sample included 42 participants: 23 receiving IVIG and 19 receiving placebo. At week 12, Total Improvement Score was 60.0 (95% CI 52.6–67.4) versus 42.5 (95% CI 30.6–54.4), p = .01. Moderate improvement occurred in 91% versus 53%. Trial identifier: EudraCT2020-001710-37-NL.

Limitations: This was a single-center study with short follow-up and a disease-specific composite endpoint. It does not establish healthy muscle gain or muscle preservation during GLP-1 treatment. The major-response analysis was post hoc. Full supplemental analyses were not reviewed.

Safety: One asymptomatic deep-vein thrombosis occurred in the IVIG group.

U.S. status: No new U.S. label action established by this publication.

Next milestone: Further comparative evidence and longer follow-up are undated.

JAMA Neurology September14 publication.

Primary topic: Autoimmune disease and immune reset. Stable event key: IVIG_2026-09-14_TIME-IS-MUSCLE.

Completed finerenone–semaglutide combination study appears in registry

Source date: 2026-09-14. Evidence: New retrospective trial registration.

A newly posted human trial will be followed for results; it is not a new trial launch. NCT07819227 was first posted on September 14. The open-label, randomized phase 2 crossover study enrolled 41 participants, started on February 11, 2025 and completed on August 31, 2026. Its primary endpoint is the proportion achieving at least a 30% reduction in UACR during single-drug or combination treatment through week 37.

Limitations: Registered after completion, without posted results. Albuminuria endpoint is not kidney-failure prevention.

Safety: No trial results available.

U.S. status: No new combination indication established.

Next milestone: Publication or posted results undated.

NCT07819227 current primary registry.

Primary topic: Kidney preservation and earlier detection. Stable event key: finerenone-semaglutide_2026-09-14_retrospective-registration.

JNJ-5120/PIPE-307 failed the MOONLIGHT-1 primary depression endpoint

Source date: 2026-09-14. Evidence: sponsor topline randomized phase 2.

Contineum reported that MOONLIGHT-1 did not improve Day 5 MADRS significantly versus placebo. Randomized, double-blind monotherapy study in adults with MDD; NCT06785012. Registry actual enrollment 107, completed August 10, last updated August 28, no posted results. The selective M1 inhibitor is licensed to J&J. Prespecified exploratory analyses continue; no program discontinuation was announced.

Limitations: No effect size, confidence interval or P value in topline. A later exploratory signal would not erase the failed primary endpoint.

Safety: Sponsor reports no new safety signal; detailed adverse-event rates not released.

U.S. status: Investigational for MDD.

Next milestone: No announced date: Full results and J&J development decision remain pending.

September 14 issuer release filed with SEC; MOONLIGHT-1 registry.

Primary topic: Mental-health treatments, SSRIs and newer antidepressants. Stable event key: pipe307_moonlight1_primary_failure_2026_09_14.

Photothermal PRP does not outperform conventional PRP on melasma severity

Source date: 2026-09-12. Evidence: peer-reviewed randomized human study; original abstract reviewed.

A small split-face trial found no superiority on clinician-rated melasma severity despite a difference in instrument-measured pigmentation. TCTR20260318004; 26 women received three monthly sessions, with photothermal-activated and conventional PRP on opposite sides. At 12 weeks both mMASI scores improved; no between-treatment difference at any assessment. Photothermal PRP had lower melanin index at week 12.

Limitations: No untreated/sham side, short follow-up, small female-only sample. No numerical between-group effect or confidence interval in abstract; nonsignificance is not proof of equivalence. Publisher contents page verifies first publication September 12.

Safety: Mild injection-site bruising was the only reported adverse event; sample cannot resolve uncommon harms.

U.S. status: No U.S. melasma approval established by this trial.

Next milestone: Larger trials and relapse follow-up; no announced date.

Original PubMed abstract; Publisher DOI; Publisher contents verifying date.

Primary topic: Pigmentation and uneven skin tone. Stable event key: PRP_melasma_2026-09-12_photothermal_randomized.

Silica-enriched toothpaste improves sensitivity but not measured mineral gain

Source date: 2026-09-12. Evidence: peer-reviewed pilot randomized human study; abstract reviewed.

A pediatric enamel-defect trial found a pain-sensitivity signal but no superiority over fluoride toothpaste on its mineral-gain endpoint. RBR-6d3g5hp / U1111-1327-7119; triple-blind pilot, 30 children aged 6–12, 95 teeth, 45 days. REFIX Booster versus 1450 ppm fluoride. Between-group change in fluorescence ΔF: −0.43 percentage points, 95% CI −2.73 to 1.86, p=.711; ΔFmax also nonsignificant. Sensitivity improved more, p=.011. Models accounted for teeth clustered within children.

Limitations: Short pilot; fluorescence is a surrogate, not replacement of missing enamel or tooth regeneration. No relevant aesthetic difference; secondary pain signal needs replication.

Safety: No adverse effects reported in this small short study.

U.S. status: No new U.S. authorization or availability established.

Next milestone: Definitive trial and durability follow-up undated.

Original abstract; Original DOI.

Primary topic: Dental alignment, regeneration and repair. Stable event key: REFIX_2026-09-12_MIH_pilot_negative_mineralgain.

Advertising review challenges precision claims for embryo selection

Source date: 2026-09-11. Evidence: Advertising self-regulatory decision; appeal announced.

NAD recommended changing or discontinuing specific Nucleus IVF+ embryo-comparison claims; Nucleus announced an appeal. The decision questioned whether submitted evidence validated ranking a group of sibling embryos and the advertised numerical differences in disease risk, height and IQ, as well as definite eye/hair-color predictions.

Limitations: This is an advertising self-regulatory finding, not an FDA ban, a new clinical trial, or a determination that all genetic testing lacks value. Keep it separate from inherited-disease PGT-M and the non-invasive PGT-A trial.

Safety: No new clinical safety outcome was measured.

U.S. status: Commercial offering and claim substantiation are separate; no change in FDA authorization is established.

Next milestone: Appeal outcome; no date announced.

NAD decision, September 11.

Primary topic: Genetic screening and risk prediction. Stable event key: nucleus_ivf_2026-09-11_nad_advertising_decision.

An antimicrobial peptide is being tested against prosthetic-joint infection

Source date: 2026-09-11. Evidence: Investigator enrollment report and trial registry.

WVU reported its first participant in RETAIN, a controlled trial of PLG0206 irrigation alongside surgery and antibiotics for infected knee replacements. NCT07214311 is a recruiting randomized placebo-controlled phase 2/3 study targeting 240 participants. It measures treatment failure through 12 months after debridement, antibiotics and implant retention, with surgery, survival and function also tracked. The registry lists a February 3, 2026 global start; September is a site-enrollment report, not global trial initiation.

Limitations: This newly added formal antimicrobial program addresses biofilm-associated infection, not cartilage regeneration. Laboratory activity and earlier small studies do not establish superiority, broad resistant-infection efficacy or implant retention benefit.

Safety: No new comparative efficacy or safety results were reported.

U.S. status: Investigational; Orphan/Fast Track/QIDP designations are not approval.

Next milestone: September 2028 primary completion is the September 18 registry estimate; public results timing is unknown.

WVU investigator update, September 11; RETAIN registry.

Primary topic: Infectious-disease prevention and treatment. Stable event key: plg0206_2026-09-11_retain_site_enrollment.

Early BEST1 gene-therapy findings include a corrected visual-acuity chart

Source date: September 9 announcement; corrected September 11. Evidence: sponsor phase 1/2 topline and SEC correction.

Opus reported early visual-test signals in five BIRD-1 participants on September 9 and corrected the visual-acuity conversion on September 11. NCT07185256; three BVMD participants had three-month follow-up, two ARB participants six months. The company reported gains on at least one visual test per participant; denominators vary by measure. September 11 correction gives treated-eye three-month ETDRS changes +12, +1, −10, +2 and +6 letters, versus fellow-eye +4, −7, −8, −5 and +2. Use revised presentation, not the original mean chart.

Limitations: Open-label n=5, multiple outcomes and mixed follow-up; fellow eyes are not a randomized control. Restricted to inherited BEST1 retinal disease, not common AMD. Registry enrollment estimate 10 predates sponsor cohort expansion.

Safety: No serious adverse events, dose-limiting toxicities or intraocular inflammation reported; related AEs mild/moderate. Long-term and rare risks unresolved.

U.S. status: Investigational; reported FDA endpoint discussions are not approval.

Next milestone: Scheduled presentation / sponsor forecast: EURETINA October 4, 2026, 13:15–13:21 CEST; cohort 2 dosing completion Q4 2026, further data Q2 2027 and potential pivotal dosing in 2027.

September 9 issuer data; September 11 correction; Conference schedule; BIRD-1 registry.

Primary topic: Hearing and vision preservation/restoration. Stable event key: opgx_best1_bird1_cohort1_2026_09_09_corrected_09_11.

Platelet concentrates improve early extraction healing and selected bone dimensions

Source date: 2026-09-11. Evidence: peer-reviewed randomized human study; accepted early article.

A 60-person extraction trial found early healing and imaging gains with blood-derived concentrates; it did not study new teeth or long-term tooth retention. TCTR20251028003, retrospectively registered. Impacted lower-third-molar extraction; 20 each advanced platelet-rich fibrin, concentrated growth factors, natural healing. Both interventions improved early pain/swelling/healing. At 3 months A-PRF buccal-wall height change +1.32 ± 0.72 mm versus +0.01 ± 1.6 mm with CGF and −0.07 ± 1.12 mm controls; both preserved width.

Limitations: One small extraction setting; accepted version may be edited. Three-month radiographic dimensions do not establish durable functional regeneration or superior implant survival.

Safety: Accessible abstract does not provide a complete adverse-event table.

U.S. status: No new FDA authorization or generalized dental-regeneration claim.

Next milestone: Longer comparative follow-up undated.

Original accepted paper.

Primary topic: Dental alignment, regeneration and repair. Stable event key: APRF_CGF_2026-09-11_dental_ridge_RCT.

Rapamycin pilot reports brain-perfusion increases in APOE4 carriers

Source date: 2026-09-10. Evidence: Peer-reviewed single-arm human pilot.

A four-week study reports a cerebral blood-flow signal in cognitively normal APOE4 carriers; it did not test prevention of dementia or longer life. Twenty-three adults aged 45–65 completed the study: nine APOE4 carriers and 14 noncarriers. They received rapamycin 1 mg/day for four weeks. The primary cerebral blood-flow endpoint increased by more than 15% in multiple regions among carriers; noncarriers had no significant change. Secondary metabolic, inflammatory and microbiome measures were explored. DOI: 10.1177/0271678X261490342.

Limitations: There was no placebo or control treatment. Genotype groups were tiny, follow-up lasted four weeks, and multiple exploratory measures were examined. Appraisal was limited to the abstract; detailed safety tables and the registry record were not retrieved.

Safety: The abstract describes minimal adverse effects but provides no event counts; long-term safety cannot be inferred.

U.S. status: Rapamycin is not approved for longevity or Alzheimer’s prevention.

Next milestone: No date for a subsequent trial or readout was verified.

Original PubMed abstract.

Primary topic: Longevity and healthspan trials. Stable event key: rapamycin_2026-09-10_APOE4-CBF-pilot.

HERMES trial is terminated

Source date: 2026-09-10. Evidence: Trial-registry development update.

Fresh registry confirms ziltivekimab HERMES termination, superseding the earlier continuation forecast. NCT05636176 lists 4,899 actual participants, actual completion September 3 and last update September 10. No results posted. This is a heart-failure program followed as context to the broader ziltivekimab prevention program.

Limitations: The reason field says only that the trial is no longer looking for participants. The registry alone does not establish futility or a safety cause. ATHENA, NCT06200207, remains active and not recruiting in an older September 1 record, so later reports that it stopped remain unreconciled.

Safety: No new safety or outcome estimates posted.

U.S. status: Investigational.

Next milestone: Detailed program explanation and full ZEUS results undated.

NCT05636176 current primary registry; NCT06200207 current primary registry.

Primary topic: Broad cardiovascular prevention, lipids and screening. Stable event key: HERMES_2026-09-10_terminated.

ALZ-101 phase 2 enters operational preparation

Source date: 2026-09-10. Evidence: sponsor trial-development announcement.

Alzinova announced operational start-up of its therapeutic Alzheimer vaccine phase 2 study, not first enrollment or dosing. Global randomized placebo-controlled study plans about 120 early-AD participants, ADCOMS change at 52 weeks as primary endpoint and 92-week total follow-up. CRO kick-off completed; regulatory/ethics submissions and site preparations ongoing.

Limitations: Preparation is not recruiting status or efficacy evidence. No matched phase 2 registry ID verified.

Safety: No new safety result in announcement.

U.S. status: Investigational therapeutic vaccine, not approved prevention.

Next milestone: Sponsor forecast: First enrollment around the turn of 2026/2027; no results date announced.

September 10 issuer release.

Primary topic: Alzheimer's screening and therapies. Stable event key: alz101_phase2_operational_startup_2026_09_10.

Inhaled RNA interference reaches human lung target-engagement evidence

Source date: 2026-09-09. Evidence: Peer-reviewed randomized phase 1/2a study.

ARO-RAGE reduced its lung inflammatory target in early human research; fewer asthma attacks or COPD benefit have not been demonstrated. NCT05276570 studied healthy volunteers and mild-to-moderate type-2 asthma. The published cohorts include 58 treated healthy volunteers and 19 treated asthma patients, with 29 placebo participants. The study focused on safety and target engagement; pulmonary-function measures were safety assessments, not powered efficacy tests.

Limitations: The registry lists 127 overall participants, while the published cohorts total 106; the abstract active-treatment counts must not be represented as all randomized participants. No clinical-outcome benefit is inferred from soluble-RAGE reduction.

Safety: Headache and respiratory infections were common. COVID-19 occurred in 14/58 treated healthy volunteers versus 2/23 placebo. One delayed pre-eclampsia serious event was assessed unrelated; no asthma serious events. Small cohorts cannot settle uncommon harms.

U.S. status: Investigational inhaled siRNA; no U.S. approval.

Next milestone: Separate phase 2a NCT07241546 is recruiting (target 36); primary completion December 2027 is a registry estimate, not a promised readout.

Nature Medicine, September 9; Original full text; Next study.

Primary topic: Allergy and airway disease. Stable event key: aro_rage_2026-09-09_phase1_2_publication.

COMP005 reports one-year follow-up with additional psilocybin doses

Source date: 2026-09-09. Evidence: sponsor topline open-label extension.

COMP005 Part C reported improvement through week 52 after permitted additional COMP360 dosing. Original trial randomized 258 people with TRD. Approximately 70% entered open-label weeks 26–52; 90 originally assigned 25 mg received a second or third dose and 52 originally assigned placebo received their first 25 mg dose. Sponsor reports a 13-point mean baseline-to-week-52 MADRS reduction in the original active-arm repeat-dose group, with 40–45% response and about 30% remission over six weeks after Part C dosing.

Limitations: Open-label, selected continuation, attrition and redosing. This is not randomized evidence that one dose lasts a year; confidence intervals and complete denominators at each time point not supplied.

Safety: No new safety findings reported; detailed rates absent.

U.S. status: Investigational; rolling filing is not approval.

Next milestone: Sponsor forecast: Rolling NDA completion Q4 2026; conditional U.S. launch H1 2027, subject to approval/rescheduling.

Compass September 9 extension topline.

Primary topic: Psilocybin and related therapies. Stable event key: comp005_partc_redosing_2026_09_09.

Non-invasive embryo chromosome screening does not improve the primary pregnancy outcome

Source date: 2026-09-08. Evidence: Peer-reviewed randomized trial; accepted early article.

A large randomized trial found no significant improvement in ongoing pregnancy or live birth after the first transfer with non-invasive PGT-A versus morphology-based selection. NCT04339166 enrolled women aged 35–42 with at least two blastocysts at 13 Chinese centers. The modified intention-to-treat analysis included 1,152 couples: ongoing pregnancy beyond 12 weeks was 38.7% (221/571) versus 36.8% (214/581), adjusted p=.49; live birth was 37.0% versus 35.5%, p=.59. Early miscarriage was lower in a secondary analysis.

Limitations: This tests cell-free DNA from embryo culture medium, not embryo-biopsy PGT-A or polygenic PGT-P. First-transfer success is not cumulative live birth per retrieval. The abstract lists 1,189 allocated and 1,152 analyzed; these denominators are kept distinct.

Safety: No serious adverse events reported; maternal/neonatal differences were not significant. Long-term offspring outcomes were not established.

U.S. status: Research result, not a new U.S. authorization or proof of routine clinical utility.

Next milestone: Final publication and further clinical-utility evidence; no dependable next date.

Original trial, September 8; Trial registry.

Primary topic: Genetic screening and risk prediction. Stable event key: nipgta_2026-09-08_randomized_first_transfer.

Alzheimer Tau Platform adds combination-treatment research

Source date: 2026-09-08. Evidence: recovered baseline; current trial registry.

The Alzheimer Tau Platform is an existing recruiting phase 2 program studying tau therapies alone or with donanemab. NCT06957418, USC; master-protocol planned enrollment 900, actual start July 6, 2026. Adults 50–80 with late preclinical/early prodromal AD. Launch regimen AADvac1; later Tau2 regimen is unnamed. Randomized masked comparisons include tau therapy alone, combination and donanemab alone; primary outcome tau PET reduction.

Limitations: Master-protocol target is not enrollment for each arm. Biomarker primary outcome is not established cognitive benefit, and no results are posted.

Safety: No new safety data; combination safety remains under study.

U.S. status: Investigational regimen; donanemab approval does not authorize this preventive/combination use.

Next milestone: Registry estimate: Primary/overall completion August 31, 2028; no announced publication date.

Tau Platform master protocol.

Primary topic: Alzheimer's screening and therapies. Stable event key: alzheimers_tau_platform_baseline_recovered_2026_09_18.

Higher-dose vitamin D does not prevent fractures in a largely sufficient population

Source date: 2026-09-07. Evidence: Peer-reviewed randomized trial; primary abstract reviewed.

The Finnish FIND trial found no fracture reduction from 1,600 or 3,200 IU/day in older adults who were largely vitamin-D sufficient. NCT01463813 randomized 2,495 adults to the two doses or placebo. Over mean 4.1 years of supplementation, fractures numbered 73, 52 and 49 respectively: HR 1.52 (95% CI 1.06–2.18) for 1,600 IU and 1.07 (0.72–1.58) for 3,200 IU versus placebo. Extended follow-up also showed no benefit.

Limitations: Baseline vitamin D was measured in a 550-person subcohort (mean 74.8 nmol/L). This does not answer treatment of established deficiency or all high-risk osteoporosis populations. No simple dose-response explanation is established by the lower-dose imbalance.

Safety: The increased fracture rate in the 1,600-IU group is retained as a safety-relevant finding; fracture subtypes did not differ significantly. Detailed non-fracture adverse events were not available in the abstract.

U.S. status: A research result, not a new drug approval or individualized supplementation instruction.

Next milestone: Full-paper appraisal and replication; no dated next milestone.

Original abstract, September 7; Article.

Primary topic: Bone health, joint preservation and cartilage repair. Stable event key: find_vitamin_d_2026-09-07_fractures.

Previously inaccessible melasma pilot now appraised from indexed original text

Source date: 2026-09-07. Evidence: peer-reviewed pilot randomized human study; gap resolution.

A multicomponent cosmetic cream and triple-combination comparator both improved short-term melasma scores; equivalence was not established. Singapore single-blind split-face pilot, 30 enrolled, 56 days. Cream includes tomato extract, cysteamine, niacinamide and other ingredients. Mean mMASI changes were −1.471 with cosmetic cream and −1.394 with tretinoin/hydroquinone/fluocinolone comparator.

Limitations: Small feasibility-based sample; not powered for noninferiority, different application schedules, no post-treatment relapse follow-up. Cannot attribute the effect to tomato extract alone. Direct page is under maintenance; indexed primary methods/abstract/discussion were readable.

Safety: Mild self-limited adverse events reported, 6.7% per arm; does not establish long-term safety.

U.S. status: Cosmetic formulation study, not a new FDA-approved melasma indication.

Next milestone: Confirmatory controlled study and post-treatment follow-up undated.

Original paper.

Primary topic: Pigmentation and uneven skin tone. Stable event key: melasma_2026-09-07_multicomponent_cream_pilot.

PrevenTRON opens a UK prevention-study site

Source date: 2026-09-05. Evidence: trial-investigator site announcement.

Surrey and Borders NHS announced that its PrevenTRON site opened for asymptomatic people at elevated Alzheimer risk. Phase 3 trontinemab prevention study plans about 1,600 adults aged 55–80 worldwide; blood biomarkers aid enrollment. Source supports UK/Europe site opening and recruitment invitation, not exact first-dosing date.

Limitations: No prevention outcome data. Do not conflate this asymptomatic cohort with symptomatic TRONTIER or approved symptomatic anti-amyloid treatment.

Safety: No new trial safety findings reported; clinical monitoring remains part of investigational treatment.

U.S. status: Trontinemab prevention remains investigational.

Next milestone: No announced readout date: Track first dosing, matching registry and prevention outcomes.

September 5 NHS investigator announcement.

Primary topic: Alzheimer's screening and therapies. Stable event key: preventron_uk_site_launch_2026_09_05.

Previously inaccessible metformin biomarker trial recovered

Source date: 2026-09-03. Evidence: Historical evidence recovered.

The September 3 paper resolves a prior access gap but measures cellular biomarkers rather than healthspan. The trial randomized 127 North Indian adults aged 30–60 with prediabetes; 112 completed 24 weeks. Leukocyte telomere elongation was 29.6% with metformin versus 4.4% with placebo (between-group p < .0001). Trial identifier: NCT07302932.

Limitations: No survival, disability or disease-incidence endpoint; marked biomarker response needs replication. Registry first posted December 24, 2025, after actual January 30, 2025 completion: retrospective registration. Registry reports 112 enrolled, whereas the publication reports 127 randomized and 112 completers. Preserve those distinctions. December 2026 issue date is not original publication date.

Safety: The publisher reports early mild gastrointestinal symptoms in eight participants (14.3%) receiving metformin and two (3.6%) receiving placebo. These resolved without discontinuation, and no serious adverse events occurred. The percentages use completers rather than randomized participants as denominators.

U.S. status: No longevity indication.

Next milestone: Larger and longer replication studies are undated. TAME remains in fundraising; a funded launch was not verified.

Original abstract; Publisher paper and safety excerpt; Original trial registry, freshly retrieved September 18.

Primary topic: Longevity and healthspan trials. Stable event key: metformin_2026-09-03_telomere-rct.

RNAi liver program advances into MASH patient cohorts

Source date: 2026-09-03. Evidence: Historical evidence recovered.

TGM-312 adds a liver-targeted SLC25A5 RNAi program to the watch. The phase 1/2 RESTORE-MASH study advanced from single-dose cohorts of healthy volunteers to multiple-dose cohorts of patients with MASH after a monitoring review. Four healthy-volunteer cohorts had been dosed; the participant count was not reported.

Limitations: No numerical human liver-efficacy findings were provided. Preclinical combination and fibrosis results remain animal evidence. The registry identifier was not verified.

Safety: The sponsor reports no serious or severe adverse events in the healthy-volunteer cohorts; this is limited early safety evidence.

U.S. status: Investigational.

Next milestone: The sponsor forecasts interim results from MASH patient cohorts during 2027.

Tangram September3 original release.

Primary topic: Liver health and noninvasive assessment. Stable event key: TGM312_2026-09-03_RESTORE-MASH-patient-cohorts.

Focused-ultrasound body-contouring study registered

Source date: 2026-09-03. Evidence: Historical evidence recovered.

Linear Z adds a formal human device study for lower-abdomen and flank contouring. NCT07802431 was first posted on September 3 and is listed as recruiting. It plans to enroll 30 participants in a single-group, open-label study. Its primary endpoint is circumference change at day 90.

Limitations: No sham comparator, no results, circumference is not equivalent to measured fat volume or cellulite improvement. September 1 start remains estimated, not confirmed first enrollment.

Safety: Safety data pending.

U.S. status: This registration does not establish a U.S. clearance or approval.

Next milestone: Registry estimates primary completion December 20 and overall completion December 31, 2026; no release date.

NCT07802431 current primary registry.

Primary topic: Localized fat removal and cellulite. Stable event key: LinearZ_2026-09-03_new-human-study.

Older missing ZEUS negative outcome and infection signal

Source date: 2026-07-31. Evidence: Historical evidence recovered.

Ziltivekimab lowered inflammation but did not lower MACE in ZEUS. ZEUS enrolled more than 6,300 participants with established atherosclerotic cardiovascular disease, CKD and hsCRP of at least 2 mg/L. The hazard ratio for three-component MACE was 0.99 (95% CI 0.88–1.11).

Limitations: The July 31 announcement was omitted from the baseline; it is not a new September trial result. Numerical infection counts remain unavailable. The failure should not be generalized to every anti-inflammatory target.

Safety: Overall adverse-event and serious-adverse-event rates were similar between groups, but serious infections were more frequent with ziltivekimab. No difference in all-cause mortality was observed.

U.S. status: Investigational.

Next milestone: Full results are expected at an unspecified 2026 scientific meeting. The July forecast that HERMES would continue must be updated against its termination record.

Novo original July31 announcement.

Primary topic: Broad cardiovascular prevention, lipids and screening. Stable event key: ziltivekimab_2026-07-31_ZEUS-negative.

Rumors and informal signals

• ac102_reddit_email_2026_08_29_phase3_tinnitus_2027 — unconfirmed: Reddit user ferttt2 says an AudioCure email reported completion of the active acute-sudden-hearing-loss study phase and conditional phase3 and possibly tinnitus trials in 2027. Direct page shows text and author; indexed original gives August 29 date. Completion and plans remain secondhand. Current NCT05776459 record is stale and does not confirm 2027 dates; it concerns acute ISSNHL, not demonstrated chronic-tinnitus efficacy. Original source. newly recovered older informal signal
• obicetrapib_attia_davidson_2026_09_14_alz_prevention_discussion — unconfirmed: Michael Davidson discussed obicetrapib Alzheimer biomarker evidence and the need to test clinical prevention benefit on The Drive #407. Verified original public chapter notes, not complete paid transcript. No new controlled cognitive outcome or dated prevention-trial promise inferred. Do not treat episode itself as efficacy evidence. Original source. new attributed informal research direction
• resilient_mdma_refiling_2026_08_12_anonymous_sources — unconfirmed: Existing anonymous-source report says Resilient resubmitted its MDMA/PTSD application. Original article rechecked; no verified FDA acceptance, decision date, approval or material retraction found. Preserve existing topic history and attach this stable key if missing from ledger. Original source. No material change; no repeat alert.
• clascoterone_2026-07-26_reddit_us-launch-inference — unconfirmed: Existing Reddit inference of late-2027/2028 availability remains unconfirmed. The current inspected Cosmo primary statement gives intended U.S. filing in Q1 2027 and Europe in Q2 2027; neither is an approval or launch date. No repeat alert. Original source. No material change; no repeat alert.
• bq002_2026-05-01_reddit_phase1-2027 — unconfirmed: Existing BQ002 Phase 1/2027 rumor remains unconfirmed. BioQ describes an injectable repigmentation program but the inspected primary page does not supply a dated candidate-specific human trial registration, readout or numerical clinical results. General clinical-stage wording does not verify BQ002 phase or timing. No repeat alert. Original source. No material change; no repeat alert.

Coverage by topic

Whole-body MRI

Coverage: partial. HERCULES original registry and recent human screening-outcome discovery; unchanged stale April 2025 record, no new outcome verified.

Remaining gaps:

• ACR/CAR and full repeat-screening literature not comprehensively reopened; 327-person older observational paper is not a new September outcome.

Informal sources: MRI/Galleri podcast and Reddit searches surfaced commercial prevention discussion (including secondhand Sept4 Hyman episode), not a specific new attributable trial-result rumor; full recordings not reviewed.

Checked sources: Source 1; Source 2.

Galleri and organ-specific cancer screening

Coverage: partial. FDA September 23 notice, PATHFINDER2/REACH/Vanguard registry refresh and screening discovery; no new clinical outcome verified.

Remaining gaps:

• Substantive panel briefing package not located; full NHS/PATHFINDER tables and all Shield/Cologuard interval evidence not reappraised.

Informal sources: Recent panel speculation and podcast searches did not supply an original new quantified efficacy or approval rumor; investor recording not fully reviewed.

Checked sources: Source 1; Source 2; Source 3; Source 4.

GLP-1 and related metabolic therapies

Coverage: partial. CRB-913 new mechanism and sponsor results; Lilly EASD schedule, STEP Young repeat; Viking maintenance and major pipeline discovery queries.

Remaining gaps:

• Not every global incretin registry or safety source was refreshed.
• The Lilly page returned a 403 error, but its indexed primary announcement and PDF were readable. The original audio from Viking’s September 14 conference appearance was not reviewed.

Informal sources: Targeted Reddit and podcast searches largely returned older results and investor predictions. Viking September 14 third-party transcript found, but original conference recording not reviewed; no new result leak verified.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Muscle building and preservation

Coverage: partial. IVIG paper cross-linked from autoimmune disease; deramiocel WMS schedule; primary registry for resistance training during tirzepatide treatment. Previously recorded Isembyld and HARBOR events were deduplicated.

Remaining gaps:

• Bimagrumab, trevogrumab/garetosmab, enobosarm records not all freshly retrieved.
• Full IVIG supplement and deramiocel 24-month data unavailable.

Informal sources: September 17 CAPR stock threads infer approval from an upcoming presentation. This is unsupported investor inference, not a disclosed regulatory outcome; no new approval claim promoted.

Checked sources: Source 1; Source 2; Source 3.

Longevity and healthspan trials

Coverage: partial. Rapamycin APOE4 pilot; metformin publication and retrospective registration; AgelessRx safety correction; unchanged TAME fundraising status. RESTOR remains recruiting in its June 1 registry snapshot, with estimated completion in July 2028.

Remaining gaps:

• Rapamycin APOE4 detailed safety/registry not reviewed.
• Metformin full statistical analysis and registration discrepancy require deeper appraisal.
• AgelessRx larger finals trial registration/start remains unverified.

Informal sources: Rapamycin.news and podcast searches included August 26 Kaeberlein and September 1 Asprey opinions; no new human-program timing claim verified. Animal-only metformin prostate-cancer post excluded.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Localized fat removal and cellulite

Coverage: partial. Caliway news archive; fresh SUPREME, AYP-101 and tesamorelin registry records; new Linear Z device program; discovery searches for localized-fat and cellulite research. AYP-101 remains completed without posted results, and tesamorelin results are unchanged.

Remaining gaps:

• Caliway latest release remains August 31; Dercum topline unverified while September window remains open.
• SUPREME registry remains March 30 not-yet-recruiting despite later sponsor enrollment report.
• No comprehensive cellulite comparative-paper review; EASD human VAT abstract remains unreviewed.

Informal sources: Reddit fat/tesamorelin/cellulite searches mainly returned gray-market sourcing, promotion or personal experience, excluded. September 15 durability discussion supplied mechanistic speculation without new formal research.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Broad cardiovascular prevention, lipids and screening

Coverage: partial. ARO-DIMER-PA sponsor interim data and registry; previously omitted ZEUS negative and safety evidence; verified HERMES termination; broader discovery searches for lipid therapies, CAC, CCTA and AI plaque assessment.

Remaining gaps:

• Full pelacarsen HR, safety and congress date remain unavailable.
• ATHENA September 1 registry is older than reports of stopping; no original later sponsor correspondence retrieved.
• Other VERVE/olpasiran/lepodisiran records and new AI-CAC/CCTA studies not comprehensively refreshed.

Informal sources: Read September 5 r/medicine pelacarsen discussion; a November presentation expectation remains unverified by sponsor date. Podcast search mainly found older material. No complete original-recording sweep.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Alzheimer's screening and therapies

Coverage: partial. Read current topic and Sept14 gaps; checked Sept5–18 human evidence and safety/negative searches, original ALZ-101/PrevenTRON announcements and direct AHEAD/TRAILBLAZER/TRONTIER/CELIA/tau-platform/PDE4 registries. No new efficacy result from the established named programs was verified; newly recovered operational/program additions above.

Remaining gaps:

• Blood-assay recall/clearance databases and newest drug labels not comprehensively re-appraised.
• Exact PrevenTRON registry/first dosing not matched. ALZ-101 phase2 ID not verified.
• Older lithium, external-counterpulsation and XPro paper leads remain full-text baseline-appraisal gaps; temporary Sep15 report is not a completed notebook update.
• PDE4 PET NCT07169630 is recruiting with September 23 estimated start after September 18 update; no validation outcomes. Not promoted to feed.

Informal sources: Original Attia/Davidson September 14 episode notes checked with timestamps; clinical-benefit discussion is not a result. Recent Reddit Alzheimer threads largely anecdotal biomarker testing or reposts. No new independently appraised efficacy rumor.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10.

Psilocybin and related therapies

Coverage: partial. Read topic/state; checked COMP005, original FDA hearing page/agenda, Definium Psych Congress timetable, GH/Helus recent-search leads, psilocybin personality-disorder paper; direct Usona/GH001/Elumina/Redefine registries. Panorama and September 8 designation already recorded and deduplicated.

Remaining gaps:

• FDA hearing date elapsed; original page remains agenda/stream oriented. No complete transcript or policy/product decision verified. Keep October 5 comment deadline and mark proceedings appraisal pending.
• Definium original event lists September 17 and18 posters, but actual presentation files/new analyses not accessible; do not infer completion/data from timetable.
• GH001 phase3 registration, complete Helus/BPL003 status sweep remain unresolved. Elumina registry still May 11 recruiting snapshot despite July sponsor dosing-complete report; no contradictory termination inference.
• Accepted psilocybin subgroup PDF blocked; abstract used only.
• L-130 September 14 sponsor index previews phase1a results, but actual September 16 presentation not appraised; no new efficacy promoted.

Informal sources: Original anonymous-source Resilient report re-opened; unchanged unconfirmed filing/acceptance status. Reddit hearing thread reviewed as commentary, not regulatory decision. AC102 irrelevant excluded from this category; podcast-specific approval dates not verified.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11.

Mental-health treatments, SSRIs and newer antidepressants

Coverage: partial. Read full current scope; checked Sept5–18 MDD, OCD, PTSD, bipolar and addiction literature/new-registry/safety searches. Verified PIPE negative topline via SEC and direct registry; new emotional-blunting/KetSet records. DISCARD remains stale not-yet-recruiting despite elapsed start; Psych Congress materials incomplete.

Remaining gaps:

• Original J&J index lists mania/seltorexant documents for September 18, but only one unrelated plain-language summary exposed; new numerical mania results unavailable at check. July mania medical page describes depression/mixed-feature studies, not new acute-mania trial.
• Liafensine phase3, ansofaxine U.S. status and all OCD/PTSD/addiction programs not fully refreshed.
• Older Ket-BD and RECOVER leads appraised in unfinished September 15 temp report but not re-opened this run; no new claims promoted here.
• September 9 OCD epigenetic paper identified, not fully appraised; biomarker association not therapy-selection benefit.

Informal sources: Reddit antidepressant/PTSD searches mainly anecdotes, drug-access chatter or stock speculation; no distinct source-grounded new program rumor extracted. Broad original interview/podcast refresh incomplete.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8.

Bone health, joint preservation and cartilage repair

Coverage: partial. FIND fracture abstract closes earlier access gap; osteoporosis cell-study abstract, TG-C/OA07 registries and lorecivivint news.

Remaining gaps:

• Ten-person uncontrolled osteoporosis cell report full tables/concomitant therapy remain inaccessible; abstract alone insufficient for a causal fracture-prevention claim. EB613/Novadip/sprifermin not comprehensively refreshed.

Informal sources: Joint/bone Reddit and podcast search found general supplement discussion and recycled forecasts; no specific new development rumor selected.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Sleep therapies and sleep disorders

Coverage: partial. Read topic; checked narcolepsy/OSA, insomnia drug/CBT-I, circadian and RLS searches. Verified Orzeyful conditional availability and Apnimed September 8 status. Direct Brilliance3 studies, Vibrance3, SynAIRgy and Neuro-DORA records inspected; sleep–Alzheimer biomarker program recovered.

Remaining gaps:

• No completed DEA scheduling/launch verified; official sponsor still November pending DEA.
• Daridorexant daytime-function study actual start/registration and tasimelteon hearing outcome remain unresolved after targeted searches.
• CBT-I/digital/circadian/new RLS coverage selective, not full registry refresh. September 9 daridorexant abstracts are exploratory reanalyses of older trials; full current analysis not appraised.
• Vibrance3 registry June 24 lists recruiting with November 2026 completion estimate, no results; cannot infer actual current enrollment from stale record.
• RLS conference September 23–26 newly identified scheduled forum, not guaranteed readout.

Informal sources: Reddit DORA/narcolepsy/RLS queries found personal experiences and repeated reviews, not new trial or approval evidence. Gray-market DORA sourcing result excluded. Original sleep podcast sweep incomplete.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10; Source 11.

Liver health and noninvasive assessment

Coverage: partial. TGM-312 human development; NATiV3 and Paris MASH updates; discovery searches for new liver programs. The Duke resmetirom/HFpEF announcement was dated August 27, not September 16.

Remaining gaps:

• Pegozafermin, efruxifermin, efimosfermin and noninvasive-test publications were not comprehensively refreshed.
• The EMA draft agenda for September 14–17 includes Wegovy for MASH, but no final CHMP action was verified.
• The RESTORE-MASH registry identifier was not verified.

Informal sources: Liver podcast searches mainly found older CME and forecasts; no original new development claim verified. Not a complete audio/transcript sweep.

Checked sources: Source 1.

Cancer treatment, vaccines and recurrence prevention

Coverage: partial. CELESTIMO, SGT610, recent FDA oncology index and WCLC/new-program discovery, with prior Sept14 reports deduplicated.

Remaining gaps:

• PAPILLON final OS/COPERNICUS details and full WCLC abstracts not appraised; broad oncology pipeline remains selective. No newly named INTerpath full-data meeting verified.

Informal sources: Original Reddit Moderna/REGAL discussions searched; largely interpretation/reposts/event-count inference. No specific sourced new efficacy or readout-date rumor selected; original investor talks not exhaustively reviewed.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Autoimmune disease and immune reset

Coverage: partial. Rap-cel/zola-cel/RESET original registries plus new human autoimmune and restart searches; old registry status cannot confirm resumption.

Remaining gaps:

• No authoritative rap-cel/zola-cel restart notice found; other allogeneic/in-vivo programs and full conference transcripts not comprehensively reviewed.

Informal sources: Reddit repeated late-August pauses. Indexed Sept9 Cabaletta conference claims about safer manufacturing remain sponsor interpretation; no verified comparative safety conclusion or new restart rumor selected.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Non-opioid pain treatments

Coverage: partial. Ketamir-2 planned phase2 original release, suzetrigine DPN and orthopedic registry refresh, Mohs paper metadata.

Remaining gaps:

• Mohs paper has no retrieved abstract/full results; VX993/Tonmya and other pain mechanisms not fully refreshed. Orthopedic registry start is September month-only estimate, not confirmed Sept30 initiation.

Informal sources: Suzetrigine podcast/CAPC talk leads found; full recordings not reviewed. Secondary Ketamir stories incorrectly implied initiation; original says Q1 2027 forecast, not current dosing.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Kidney preservation and earlier detection

Coverage: partial. Kerendia September 17 approval and current label; completed finerenone/semaglutide study retrospectively registered September 14; wider kidney discovery queries.

Remaining gaps:

• No FDA action letter retrieved; current September U.S. prescribing information confirms the T1D indication.
• Disease-specific pipelines and early-detection trial census incomplete.

Informal sources: Read September 13/16 r/IgANephropathy discussion: interpretation of finerenone guidelines rather than new trial evidence. ADPKD trial-start posts found, original confirmation incomplete.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Hearing and vision preservation/restoration

Coverage: partial. Read topic and prior gaps; checked acquired/inherited hearing and retinal trial news/safety, original OPGxBEST1 releases plus correction, PST611 repeat data and milestone, direct Rincell/AC102/PST611/BIRD1 records. Distinct populations retained.

Remaining gaps:

• PRIMA/Otarmeni current labels/regulator safety and availability not comprehensively refreshed.
• SENS601 August 31 authorization/Annexon ARCHERII older leads remain source-appraisal gaps; avoid calling September reposts new.
• ACHIEVE secondary biomarker study identified, likely first online September 3 (outside overlap), full source403 and date not confirmed from primary; no effect claim promoted.
• AC102 registry January 16 still active-not-recruiting with elapsed July 31 estimated completion; does not confirm rumored phase3/tinnitus plans.
• PST611 registry8 enrolled versus sponsor6 treated requires clarification; no unsupported pooling.

Informal sources: Original AC102 Reddit reported-email source reviewed, exact post date recovered from indexed original as August 29. 2027 trial forecast remains unconfirmed. Other hearing/vision Reddit findings were stock reposts or general timelines; no independent corroboration.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7; Source 8; Source 9; Source 10.

Hair loss, restoration and graying

Coverage: partial. Focused Sep 5–18 human-drug, regulatory and trial-registry review, with overlap against Sep 14 notes. PP405 AWAKEN is a new material registration. Rechecked Pelage, Veradermics, Cosmo and original ABS-201 registry; searched alopecia areata and biological graying. Existing clascoterone filing, VDPHL01 and ABS-201 forecasts were not re-alerted.

Remaining gaps:

• Kintor KX-826/GT20029 current Chinese original reports and matching registries were not independently resolved in this pass.
• Alopecia areata and graying searches yielded no verified new in-window material development, but the full worldwide pipeline was not exhaustively checked.
• AWAKEN first dosing is unverified; not-yet-recruiting status and month-only estimated dates are retained.

Informal sources: Targeted Reddit and podcast/talk searches. Sep 16 PP405 Reddit registration discussions led to primary registry verification; assertions that dosing already started are not confirmed. Existing clascoterone launch inference and BQ002 Phase 1/2027 rumor were revisited without confirmation. No new attributable podcast readout claim recovered.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Skin aging, laxity and regeneration

Coverage: partial. Searched human skin-quality, tightening, regenerative and device developments, including medical-weight-loss populations. Appraised Sep 17 AbbVie sponsor announcement. Refreshed original KB304 registry and FDA radiofrequency microneedling communication; no new FDA update was found on the existing safety notice.

Remaining gaps:

• Allergan full posters, original protocols, enrollment denominators and adverse-event tables were not available publicly in reviewed material.
• KB304 original registry has stale estimated completion dates and no results; 2027 Phase 2 sponsor guidance is not a confirmed start.
• NCT07661004 LED-mask/serum record was first posted June 22, not September; September estimated start remains unverified.

Informal sources: Searched Reddit, podcast and talk leads. Reviewed Sep 8 Fill Me In episode description on injectables and regenerative combinations; no original trial readout was supplied and audio/transcript was not reviewed. Third-party summaries of skin-regeneration podcasts were not treated as clinical evidence.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Scar prevention, treatment and stretch marks

Coverage: partial. Searched human scar prevention/revision drugs, verteporfin, anti-fibrotic programs, procedures and safety updates. Refreshed three original registries and Syntara news. No newly appraised human efficacy result suitable for an alert; a newly published research-letter access gap persists.

Remaining gaps:

• Sep 8 SPARC/IL-4 siRNA research letter remains inaccessible without abstract/full results. No efficacy conclusion drawn. Original NCT06138964 status is UNKNOWN with stale 2024 estimates.
• Geneva verteporfin NCT06944249 and SCARFREE NCT07488988 still say not yet recruiting despite elapsed estimated starts; no results.
• Syntara July scar guidance remains a forecast; actual new recruitment/readout not independently confirmed.

Informal sources: Targeted Reddit and podcast/talk searches found self-experimentation and promotional claims of verteporfin scarless healing without a new formal human report. These were not elevated to program rumors or efficacy updates. Reviewed description of a Sep 1 scar podcast, outside overlap and general care rather than new trial data.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6; Source 7.

Facial volume restoration and contour

Coverage: partial. Searched formal filler, biostimulator, fat-grafting, durability and safety developments. Appraised an abstract for a Sep 8 single-arm 150-person HA/PCL/PLA nasal-contour series; omitted as a minor uncontrolled, three-month study. No material newly verified comparative development or regulatory change was found in the focused review.

Remaining gaps:

• Full hybrid-filler paper was inaccessible; abstract is insufficient for longer-term safety or biocompatibility claims.
• HA-collagen RCT in a September issue was first published August 30, outside overlap; its adverse-event reporting discrepancies were not resolved and no efficacy headline was promoted.
• No comprehensive worldwide device-clearance inventory or long-term durability review was completed.

Informal sources: Targeted Reddit and podcast/talk searches. Sep 14 personal filler-MRI account has no independently reviewed clinical record and does not establish a new treatment-development signal. Sep 8 Fill Me In episode description contains general claims without a new named trial; no transcript reviewed.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Pigmentation and uneven skin tone

Coverage: partial. Appraised Sep 12 randomized photothermal-PRP melasma abstract and recovered indexed original content of Sep 7 multiingredient-cream pilot, resolving part of the previous access gap. Refreshed original STOP-V1/STOP-V2 povorcitinib records; no posted results/new readout milestone beyond prior sponsor guidance.

Remaining gaps:

• PRP full numeric tables and confidence intervals were not accessible; original abstract distinguishes clinical score from instrumental pigment result.
• Cosmetic-cream direct publisher page was under maintenance; primary indexed methods, abstract and discussion were recovered, but complete funding and registration details were not.
• No fresh comprehensive Incyte original-source pipeline review was completed; registry refresh alone does not verify unchanged sponsor plans.

Informal sources: Targeted Reddit and podcast/talk searches found personal hydroquinone/tranexamic-acid experiences and generic procedure discussion, with no attributable new program-specific milestone rumor. Informal anecdotal efficacy was not added as formal evidence.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Acne and rosacea

Coverage: partial. Searched human acne/rosacea drug, laser/device and regulatory developments; refreshed SP0268 original registry. No material new in-window result verified. Existing Sep 3 rosacea-device actual start and older OTC-switch news were not repeated. SGT-610 Sept 17 oncology milestone was handed to root for cancer treatment, not relabeled as acne.

Remaining gaps:

• SP0268 registry remains recruiting with estimated November 30, 2028 completion and no results.
• Japanese ACCLAIM/AviClear registration was disclosed August 1, outside overlap; not a newly verified September start.
• No full transcript of the Sep 1 rosacea webinar was retrieved; its linked moisturizer study was published May 20, not a new September trial report.

Informal sources: Targeted Reddit, podcast and webinar searches found general routines and previously circulated research digests, without a traceable new SP0268 or other formal-program rumor. No podcast quotation or implied readout date added.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Dental alignment, regeneration and repair

Coverage: partial. Searched alignment, retention, root/gum health, extraction healing, enamel repair and tooth regeneration. Appraised new REFIX enamel-defect pilot and A-PRF/CGF extraction RCT. Reviewed Sep 9 retrospective clear-aligner movement-predictability paper as a lower-priority lead. Refreshed direct-printed-aligner registry; checked Toregem news for first dosing/results.

Remaining gaps:

• Toregem matching Japanese jRCT Phase IIa registry and actual first dosing were not independently retrieved; August 17 regulatory-notification review is not efficacy or U.S. availability.
• Direct-printed-aligner study remains not yet recruiting despite elapsed estimated start/primary dates and an estimated September 20 final completion; do not forecast a result from those stale dates.
• New alignment paper was retrospective, 61 patients and 447 teeth, addressing initial-series movement prediction rather than whole-course speed, root injury or retention; no alert promoted.
• REFIXX/REFIX and extraction-study full safety tables were not obtained; abstract-level limitations retained.

Informal sources: Targeted Reddit and podcast/talk searches found repeated tooth-regrowth timelines and missing-original social claims, mostly older posts. No new attributable in-window trial milestone rumor verified; generic 2030/2033/2035 availability predictions were not promoted.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5; Source 6.

Allergy and airway disease

Coverage: partial. ARO-RAGE original full text and both registry records; tozorakimab/VIASKIN and new human airway searches.

Remaining gaps:

• VIASKIN Q3 filing remains a forecast in source checked; full ERS abstracts, rademikibart exploratory subgroups and broader environmental-allergy trials remain partial.

Informal sources: Reddit/podcast and investor remarks searched; Sept18 stories repeated earlier filing plans, not verified submission. Original September investor recording not appraised.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Infectious-disease prevention and treatment

Coverage: partial. RETAIN investigator report and fresh registry; AP-SA02/PURPOSE365 registry refresh; antibiotic/antiviral/vaccine discovery.

Remaining gaps:

• June fosfomycin trial resurfaced in Sept14 commentary, not new September evidence; ENCORE original conference tables and all existing antivirals/vaccines/antibiotic launches not fully appraised.

Informal sources: Informal Reddit/podcast searches were broad with poor original-source yield; no selected new attributable rumor, not an exhaustive no-rumor conclusion.

Checked sources: Source 1; Source 2; Source 3; Source 4; Source 5.

Genetic screening and risk prediction

Coverage: partial. Original niPGT-A paper and registry, SPLENDID abstract, NAD advertising decision, newborn/PRS/embryo discovery.

Remaining gaps:

• Full SPLENDID tables, Generation follow-up, pharmacogenomic and carrier/cascade studies not comprehensively refreshed.

Informal sources: Reddit genetics/PGT discussion largely opinion or old commercial claims; no independently attributable new development rumor selected. Models and embryo-editing laboratory stories not promoted to clinical outcomes.

Checked sources: Source 1; Source 2; Source 3; Source 4.

Integrity and publication

Original source dates, prior findings are preserved. The fixed initial brief is unchanged. A source page update is not the occurrence date of an adverse event; a trial registration or local-site launch is not a new efficacy readout. The September 14 FDA hearing has moved out of upcoming milestones, with its proceedings still unappraised.

The notebook was verified before export. All twelve project validators passed, including source-rendered pages, evidence data, chart interactions and public-export privacy checks. These are automated source checks, not browser visual QA. Publication success is recorded separately in local state after the deployment completes.